Literature DB >> 10940094

Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache.

B Packman1, E Packman, G Doyle, S Cooper, E Ashraf, K Koronkiewicz, S Jayawardena.   

Abstract

OBJECTIVE: To evaluate the relative efficacy of a new solubilized formulation of ibuprofen compared with acetaminophen caplets.
METHODS: This double-blind, randomized, parallel group study evaluated 154 subjects taking a single dose of solubilized ibuprofen, 400 mg; acetaminophen, 1000 mg; or placebo for the relief of episodic tension-type headache. Time to relief was measured using a stopwatch, and overall efficacy was measured using traditional categorical pain and relief scales.
RESULTS: Ibuprofen capsules (liquigel), 400 mg, were significantly faster than both acetaminophen, 1000 mg, and placebo for all time-to-relief measures. Ibuprofen liquigel had a median time to first perceptible pain relief of 39 minutes compared with 47 minutes for acetaminophen and 113 minutes for placebo. For median time to meaningful relief, ibuprofen liquigel had a time of 39 minutes compared with 53 minutes for acetaminophen and more than 180 minutes for placebo (P</=.02 for both measures). In addition, ibuprofen liquigels demonstrated significantly superior overall analgesic efficacy compared with acetaminophen, 1000 mg, for the relief of episodic tension-type headache. Both active treatments had a side effect profile similar to placebo.
CONCLUSIONS: Although several other studies have demonstrated the overall analgesic superiority of ibuprofen to acetaminophen, this study demonstrated that the liquigel formulation also provides a clinically relevant advantage for time to analgesic effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940094     DOI: 10.1046/j.1526-4610.2000.00087.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  17 in total

1.  The use of ibuprofen plus caffeine to treat tension-type headache.

Authors:  S Diamond; F G Freitag
Journal:  Curr Pain Headache Rep       Date:  2001-10

Review 2.  Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever.

Authors:  Howard S Smith; Bryan Voss
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

Review 3.  An evidence-based update on nonsteroidal anti-inflammatory drugs.

Authors:  C K S Ong; P Lirk; C H Tan; R A Seymour
Journal:  Clin Med Res       Date:  2007-03

4.  Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.

Authors:  Adrienne E Faerber; David H Kreling
Journal:  J Gen Intern Med       Date:  2014-01       Impact factor: 5.128

Review 5.  Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults.

Authors:  Guy Stephens; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-06-16

Review 6.  Pharmacological Management of Acute Endodontic Pain.

Authors:  Asma A Khan; Anibal Diogenes
Journal:  Drugs       Date:  2021-10-07       Impact factor: 9.546

Review 7.  Current and potential future drug therapies for tension-type headache.

Authors:  Sait Ashina; Messoud Ashina
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 8.  Ibuprofen for acute treatment of episodic tension-type headache in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore; Lars Bendtsen
Journal:  Cochrane Database Syst Rev       Date:  2015-07-31

9.  A Comparison of Efficacy and Safety of Non-steroidal Anti-inflammatory Drugs versus Acetaminophen in the Treatment of Episodic Tension-type Headache: A Meta-analysis of Randomized Placebo-controlled Trial Studies.

Authors:  Yeo Jung Yoon; Ju Heon Kim; Soo Young Kim; In Hong Hwang; Mi Ra Kim
Journal:  Korean J Fam Med       Date:  2012-09-27

10.  Tension-type Headache.

Authors:  Rigmor Jensen
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.